Y mAbs Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $19,525 | $20,904 | $26,495 | $18,461 |
Gross Profit | 16,863 | 17,903 | 18,653 | 16,213 |
EBITDA | -5,604 | -6,543 | -5,834 | -8,447 |
EBIT | -6,614 | -5,936 | -8,568 | |
Net Income | -3,239 | -5,196 | -6,790 | -6,998 |
Net Change In Cash | 19,525 | 20,904 | 26,495 | 18,461 |
Free Cash Flow | 1,651 | -7,038 | -1,870 | -10,665 |
Cash | 62,293 | 60,310 | 67,234 | 68,122 |
Basic Shares | 45,318 | 45,104 | 44,875 | 44,626 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $87,685 | $84,819 | $65,267 | $34,897 |
Gross Profit | 72,434 | 73,403 | 57,700 | 32,383 |
EBITDA | -30,666 | -24,937 | -93,972 | -114,651 |
EBIT | -31,201 | -25,672 | -94,811 | -115,433 |
Net Income | -29,666 | -21,427 | -96,325 | -56,345 |
Net Change In Cash | 87,685 | 84,819 | 65,267 | 34,897 |
Cost of Revenue | 66,801 | |||
Free Cash Flow | -15,714 | -27,232 | -75,921 | -103,523 |
Cash | 67,234 | 78,637 | 105,762 | 181,564 |
Basic Shares | 44,328 | 43,645 | 43,703 | 43,181 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.07 |
2025-03-31 | -$0.12 |
2024-12-31 | -$0.15 |
